rheumatologyadvisor6h
Apremilast Enhances Outcomes in Early Oligoarticular PsA
In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.
rheumatologyadvisor6h
Patients With Rheumatoid Arthritis Frequently Have Persisting Pain
Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.
Pharmabiz13h
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
Drug Store News20h
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is a biosimilar to Stelara, a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...